Company intelligence / Profile preview
Merrimack Pharmaceuticals
- Ownership
- Public · MACK
- Development stage
- Commercial
Overview
Merrimack was a clinical-stage biopharma company developing targeted therapies for cancer. Its lead commercial product was Onivyde® for pancreatic cancer. After selling Onivyde to Ipsen in 2017 and discontinuing all remaining clinical programs due to efficacy or safety failures by mid–2019, the company ceased R&D activities and ultimately dissolved in May 2024[4][5][7].
- Therapeutic areas
- Oncology
- Modalities
- Antibodies (monoclonal and bispecific)fusion proteinssmall molecules
- Industry
- Biotech
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $224M
- Total revenue
- $0
- Enterprise value
- $-20.1M
Beyond the preview
Go deeper on Merrimack Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Merrimack Pharmaceuticals.